Discovering the Solid-State Secrets of Lorlatinib by NMR Crystallography: To Hydrogen Bond or not to Hydrogen Bond
-
Published:2023-07
Issue:7
Volume:112
Page:1915-1928
-
ISSN:0022-3549
-
Container-title:Journal of Pharmaceutical Sciences
-
language:en
-
Short-container-title:Journal of Pharmaceutical Sciences
Author:
Rehman ZainabORCID,
Franks W.TrentORCID,
Nguyen Bao,
Schmidt Heather Frericks,
Scrivens Garry,
Brown Steven P.ORCID
Subject
Pharmaceutical Science
Reference109 articles.
1. Lorlatinib: first global approval;Syed;Drugs,2019
2. A user's guide to Lorlatinib;Nagasaka;Crit Rev Oncol Hematol,2020
3. Discovery of (10R)-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
4. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial;Shaw;Lancet Oncol,2017
5. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study;Solomon;Lancet Oncol,2018
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献